KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Cash & Equivalents (2016 - 2025)

Sarepta Therapeutics has reported Cash & Equivalents over the past 15 years, most recently at $801.3 million for Q4 2025.

  • Quarterly results put Cash & Equivalents at $801.3 million for Q4 2025, down 5.08% from a year ago — trailing twelve months through Dec 2025 was $801.3 million (down 5.08% YoY), and the annual figure for FY2025 was $801.3 million, down 5.08%.
  • Cash & Equivalents for Q4 2025 was $801.3 million at Sarepta Therapeutics, up from $613.1 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for SRPT hit a ceiling of $2.1 billion in Q4 2021 and a floor of $197.9 million in Q3 2024.
  • Median Cash & Equivalents over the past 5 years was $848.1 million (2023), compared with a mean of $904.3 million.
  • Biggest five-year swings in Cash & Equivalents: tumbled 63.49% in 2024 and later skyrocketed 209.87% in 2025.
  • Sarepta Therapeutics' Cash & Equivalents stood at $2.1 billion in 2021, then tumbled by 54.31% to $966.8 million in 2022, then crashed by 55.68% to $428.4 million in 2023, then soared by 97.04% to $844.2 million in 2024, then decreased by 5.08% to $801.3 million in 2025.
  • The last three reported values for Cash & Equivalents were $801.3 million (Q4 2025), $613.1 million (Q3 2025), and $510.6 million (Q2 2025) per Business Quant data.